Swiss pharmaceutical AstraZeneca (NYSE:AZN) was 8th on the list of R&D research spending with a 2006 expenditure of $2.95 bn EUR and 7th for overall sales in 2006. AstraZeneca saw its Seroquel XR for schizophrenia get FDA approval this year and received U.S. Food and Drug Administration approval to sell its cholesterol drug, Crestor, to also treat clogged arteries. Last week the FDA issued final assessment of studies on Nexium and found there was no likely cardiac risk associated with long term use of the drug. The company has 31 Phase III drugs , 19 in Phase II and 39 in Phase I.
Pending Approval
Nexium - NSAID GI side effects – symptom resolution/ulcer healing
Seroquel - Bipolar maintenance
FluMist - Influenza virus
Symbicort - COPD
Phase III
AZD6140 - Arterial thrombosis
Saxagliptin - Diabetes
Dapagliflozin - Diabetes
Zactima - NSCLC
Recentin - NSCLC and CRC/Recurrent glioblastoma
ZD4054 - Hormone resistant prostate cancer
Motavizumab - RSV prevention
Atacand - diabetic retinopathy
Atacand Plus - 32/12.5 mg, 32/25 mg for hypertension
Crestor - Outcomes CHF
Crestor - Outcomes End Stage Renal Disease
Nexium - Peptic ulcer bleeding
Nexium low dose aspirin combination - Low dose aspirin
associated peptic ulcer
Seroquel XR - Generalised anxiety disorder
Seroquel XR - Major depressive disorder
Seroquel XR - Bipolar mania
Seroquel XR - Bipolar depression
Faslodex - 1st line advanced breast cancer
Faslodex - Adjuvant
[Source: FierceBiotech]
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 12, 2007 10:53 AM | Permalink to Trackback